睿知中国医院研究地图
候选清单

杭州浙江大学医学院

浙江大学医学院附属第一医院

First Affiliated Hospital, Zhejiang University

在本站收录的 53 种疾病中,这家医院列在其中 38 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

浙江大学医学院附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma11 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma258 篇牵头论文牵头 8 项开放试验
  4. 胃癌Stomach cancer65 篇牵头论文牵头 14 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  6. 骨肉瘤Osteosarcoma8 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour9 篇牵头论文牵头 1 项开放试验
  8. 神经母细胞瘤Neuroblastoma5 篇牵头论文牵头 1 项开放试验
  9. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma55 篇牵头论文牵头 6 项开放试验
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia5 篇牵头论文牵头 13 项开放试验
  12. 再生障碍性贫血Aplastic anaemia1 篇牵头论文牵头 1 项开放试验
  13. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis14 篇牵头论文
  14. 血友病 AHaemophilia A4 篇牵头论文
  15. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  16. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  17. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder3 篇牵头论文
  18. IgG4相关性疾病IgG4-related disease2 篇牵头论文
  19. 重症肌无力Myasthenia gravis0 篇牵头论文牵头 1 项开放试验
  20. 肝豆状核变性Wilson disease4 篇牵头论文牵头 1 项开放试验
  21. 胆道闭锁Biliary atresia2 篇牵头论文
  22. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis4 篇牵头论文
  23. 大动脉炎Takayasu arteritis1 篇牵头论文
  24. 肝包虫病Hepatic echinococcosis0 篇牵头论文
  25. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  26. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis5 篇牵头论文
  27. 法布雷病Fabry disease2 篇牵头论文
  28. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  29. 白塞病Behçet disease2 篇牵头论文
  30. Alport 综合征Alport syndrome0 篇牵头论文
  31. IgA 肾病IgA nephropathy2 篇牵头论文
  32. 戈谢病Gaucher disease0 篇牵头论文牵头 1 项开放试验
  33. 尼曼-匹克病 C 型Niemann–Pick disease type C1 篇牵头论文
  34. 成骨不全症Osteogenesis imperfecta1 篇牵头论文
  35. 原发性胆汁性胆管炎Primary biliary cholangitis4 篇牵头论文
  36. 原发性硬化性胆管炎Primary sclerosing cholangitis4 篇牵头论文
  37. 先天性巨结肠Hirschsprung disease1 篇牵头论文
  38. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、β 地中海贫血、范可尼贫血、烟雾病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025

杭州有 8 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术影像与人工智能复发与转移
论文中的科室放疗科耳鼻喉/头颈外科
牵头的论文5
  1. An isodose-constrained automatic treatment planning strategy using a multicriteria predicted dose rating.2025Medical physics免费全文
  2. Machine learning model for predicting recurrence following intensity-modulated radiation therapy in nasopharyngeal carcinoma.2025World journal of surgical oncology免费全文
  3. Salidroside suppresses the activation of nasopharyngeal carcinoma cells via targeting miR-4262/GRP78 axis.2022Cell cycle (Georgetown, Tex.)免费全文
  4. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the Global Burden of Disease Study 2019.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery免费全文
  5. Ceruloplasmin inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells and is negatively regulated by miR-543.2022Nucleosides, nucleotides & nucleic acids
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
PubMed 以外找到的论文(未计入)5
  1. Exploiting Semantic Asymmetry to Enhance the Accuracy of Gross Tumor Volume Delineation in Nasopharyngeal Carcinoma on Planning CT2025International Journal of Radiation Oncology*Biology*Physics论文
  2. Leveraging Semantic Asymmetry for Accurate Gross Tumor Volume Segmentation of Nasopharyngeal Carcinoma in Planning CT2025Lecture notes in computer science会议论文
  3. Leveraging Semantic Asymmetry for Precise Gross Tumor Volume Segmentation of Nasopharyngeal Carcinoma in Planning CT2024arXiv (Cornell University)预印本
  4. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figshare数据集
  5. Deep Learning-Based Multi-Modality Segmentation of Primary Gross Tumor Volume in CT and MRI for Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.4%。

牵头论文
11
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 1120232024: 3320242025: 332025

杭州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  2. 正在招募
    Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
    分期
    II期
    开始
    2022-08
    登记号
    NCT05507411

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院;另有 2 家列出的医院为研究中心宁波、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗免疫治疗手术
论文中的科室放疗科肿瘤内科
牵头的论文11
  1. Neoadjuvant Chemoimmunotherapy for Elderly Patients with Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.2026Annals of surgical oncology
  2. Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  3. Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrog2025European journal of medical research免费全文
  4. Long-term outcomes after Ivor-Lewis versus McKeown esophagectomy with two-field lymphadenectomy for resectable middle or lower thoracic esophageal squamous cell carcinoma.2025Langenbeck's archives of surgery免费全文
  5. COL8A1 Regulates Esophageal Squamous Carcinoma Proliferation and Invasion Through PI3K/AKT Pathway.2024Annals of surgical oncology
  6. ASO Author Reflections: COL8A1 Regulates Esophageal Squamous Carcinoma.2024Annals of surgical oncology
  7. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?2024Journal of cancer research and clinical oncology免费全文
  8. STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma.2023Redox biology免费全文
  9. Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.2022Contrast media & molecular imaging免费全文
  10. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.2022Current oncology (Toronto, Ont.)免费全文
  11. International trends in esophageal cancer incidence rates by histological subtype (1990-2012) and prediction of the rates to 2030.2022Esophagus : official journal of the Japan Esophageal Society
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT07142421牵头方II期2025-08 启动
  2. a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study状态不明NCT06472635牵头方(推断)2022-03 启动
  3. Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus已撤回NCT02033538牵头方(推断)II期2014-01 启动
  4. Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma已撤回NCT02034968牵头方(推断)II期2014-02 启动
  5. Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus已撤回NCT02041819牵头方(推断)II期2014-02 启动
  6. Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma已撤回NCT02011594牵头方(推断)II期2014-01 启动
  7. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  8. Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC正在招募NCT05507411研究中心II期2022-08 启动
  9. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  10. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  11. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  12. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  13. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  14. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  15. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  16. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)15
  1. Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology2025Research Square预印本
  2. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncology撤稿
  3. 1446P Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial2024Annals of Oncology论文
  4. Abstract 625: Remodeling of the tumor microenvironment in esophageal squamous cell carcinoma by neoadjuvant immunochemotherapy and its impact on therapeutic efficacy2024Cancer Research会议摘要
  5. Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced resectable esophageal squamous cell carcinoma: A prospective phase 2 study.2024Journal of Clinical Oncology会议摘要
  6. OA18.05 Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial2024Journal of Thoracic Oncology会议摘要
  7. The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced lymph node-positive esophageal squamous cell carcinoma: A real world study.2024Journal of Clinical Oncology会议摘要
  8. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figshare数据集
  9. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figshare数据集
  10. Comparison of Efficacy and Safety of First‐Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta‐Analysis2023Journal of Clinical Pharmacy and Therapeutics综述
  11. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  12. PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT12022Frontiers in Oncology论文
  13. 254 LYMPH NODE DISSECTION IN T1 AND T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: MINIMALLY INVASIVE ESOPHAGECTOMY VERSUS OPEN SURGERY2021Diseases of the Esophagus论文
  14. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  15. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 258 篇,占 1.8%。

牵头论文
258
2021–2025 年
牵头试验
32
任何状态,ClinicalTrials.gov
牵头的开放试验
8
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 383820212022: 505020222023: 535320232024: 555520242025: 56562025

杭州有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-01
    登记号
    NCT06676982

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 正在招募
    Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
    分期
    I/II期
    开始
    2025-04
    登记号
    NCT06995105

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  3. 正在招募
    A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
    分期
    不分期
    开始
    2025-06
    登记号
    NCT07039201

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  4. 正在招募
    Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
    分期
    I/II期
    开始
    2025-08
    登记号
    NCT07123545

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  5. 正在招募
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07359586

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  6. 正在招募
    Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2024-07
    登记号
    NCT06461624

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  7. 正在招募
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2022-02
    登记号
    NCT05155189

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 1 家列出的医院为研究中心杭州、郑州

  8. 即将招募
    Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
    分期
    早期I期
    开始
    2026-03
    登记号
    NCT07487402

    年龄 19 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  9. 正在招募
    JMT106 Injection in the Treatment of Advanced Solid Tumors
    分期
    I期
    开始
    2025-09
    登记号
    NCT07275073

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

  10. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  11. 即将招募
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07596134

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南昌、台州、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后手术与肝移植影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科肿瘤内科消化/肝病科
牵头的论文258
  1. Cross-modality fusion of hematology-based digital and molecular biomarkers for intelligent epidemiological screening and surveillance of hepatocellular carcinoma.2026Biosensors & bioelectronics
  2. Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single-Cell Resolution.2026Cell proliferation免费全文
  3. Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience.2026European radiology
  4. Tumor micronecrosis is a marker of poor prognosis of hepatocellular carcinoma after liver resection.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  5. A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  6. Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma.2026Journal of advanced research免费全文
  7. Systemic Inflammation-Based Staging System for Hepatocellular Carcinoma After Drug-Eluting Beads Transarterial Chemoembolization: A Multicenter Study.2025Academic radiology
  8. Irreversible Electroporation vs. Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma: A Propensity Score Analysis.2025Academic radiology
  9. A self-assembling cytotoxic nanotherapeutic strategy for high drug loading and synergistic delivery of molecularly targeted therapies.2025Acta biomaterialia
  10. The FBXW7-RPAP2 Axis Controls the Growth of Hepatocellular Carcinoma Cells and Determines the Fate of Liver Cell Differentiation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  11. Galectin-1-Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  12. Diagnostic value of Gd-EOB-DTPA enhanced MRI in hepatocellular carcinoma with hyperintensity on hepatobiliary phase with cirrhosis.2025BMC cancer免费全文
  13. Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study.2025BMC cancer免费全文
  14. Therapeutic outcomes of thermal ablation versus repeated hepatic resection for recurrent hepatocellular carcinoma by using propensity score analysis: a multicenter real-world study.2025BMC cancer免费全文
  15. MRI radiomics model for predicting tumor immune microenvironment types and efficacy of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma.2025BMC medical imaging免费全文
  16. Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma.2025Cancer biology & medicine免费全文
  17. Super-enhancer-associated circPVT1 promotes malignancy of hepatocellular carcinoma via YBX1-mediated RRM2 activation.2025Cancer letters
  18. WZ4003 sensitizes hepatocellular carcinoma to OSI-027 by inhibiting ARK5-mediated autophagy.2025Cancer letters
  19. Chemokines: Orchestration of the Tumor Microenvironment and Control of Hepatocellular Carcinoma Progression.2025Cancer medicine免费全文
  20. Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study.2025Cancer medicine免费全文
  21. Emerging Trends in Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: A Focus on Liver Transplant Candidates.2025Cancer reports (Hoboken, N.J.)免费全文
  22. Diverse RNA methylation patterns in neutrophils: key drivers in hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  23. Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade.2025Clinical transplantation
  24. Fibroblast Heterogeneity in Hepatocellular Carcinoma and Identification of Prognostic Markers Based on Single-cell Transcriptome Analysis.2025Current medicinal chemistry
  25. Clinical Significance of a Novel Vasculogenic Mimicry-based Prognostic Model in Hepatocellular Carcinoma.2025Current medicinal chemistry免费全文
  26. Intraindividual comparison of CT and MRI for predicting vessels encapsulating tumor clusters in hepatocellular carcinoma.2025European radiology
  27. Systemic chemotherapy improves outcome of hepatocellular carcinoma patients treated with transarterial chemoembolization.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  28. Nomogram for prediction of hepatocellular carcinoma recurrence after liver resection.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  29. Machine learning model stratify hepatocellular carcinoma patients into high- and low-risk recurrence or death group post curative resection.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  30. circ0006646 serves as a robust prognostic biomarker for post-transplant tumor recurrence and survival in hepatocellular carcinoma patients.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  31. Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis.2025Hepatology (Baltimore, Md.)
  32. Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.2025Hepatology (Baltimore, Md.)RCT
  33. NAE1 protein: a prognostic, immunomodulatory, and therapeutic biomarker associated with neddylation in hepatocellular carcinoma.2025International journal of biological macromolecules
  34. Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies.2025International journal of biological sciences免费全文
  35. Radiofrequency hyperthermia enhances the antitumor efficacy of oncolytic peptide LTX-315 in liver cancer cells by activating of cGAS-STING pathway.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  36. MYBBP1A‑mediated IGFBP4 promoter methylation promotes epithelial‑mesenchymal transition and metastasis through activation of NOTCH pathway in liver cancer.2025International journal of oncology免费全文
  37. DeepSeek-assisted LI-RADS classification: AI-driven precision in hepatocellular carcinoma diagnosis.2025International journal of surgery (London, England)免费全文
  38. Nanosecond pulsed electric field ablation as first-line curative therapy for hepatocellular carcinoma in high-risk locations a prospective multicenter.2025International journal of surgery (London, England)免费全文
  39. Construction of an artificially intelligent model for accurate detection of HCC by integrating clinical, radiological, and peripheral immunological features.2025International journal of surgery (London, England)免费全文
  40. Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis.2025International journal of surgery (London, England)免费全文
  41. Sex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis.2025JAMA network open免费全文
  42. Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition.2025Journal of advanced research免费全文
  43. Nucleolin as a Potent Biomarker for Predicting Tumor Recurrence among Patients with Hepatocellular Carcinoma after Transplantation.2025Journal of gastrointestinal and liver diseases : JGLD
  44. Resveratrol promotes mitophagy via the MALAT1/miR-143-3p/RRM2 axis and suppresses cancer progression in hepatocellular carcinoma.2025Journal of integrative medicine
  45. Downregulation of MPC1 promotes HCC cell proliferation and metastasis via the STAT3 pathway.2025Journal of molecular histology
  46. Nanoliposomal PD-1 antagonist target tumor-draining lymph nodes to revitalize T cells and improve anti-tumor effect in hepatocellular carcinoma.2025Journal of nanobiotechnology免费全文
  47. Injectable celastrol-loading emulsion hydrogel for immunotherapy of low-immunogenic cancer.2025Journal of nanobiotechnology免费全文
  48. ViT-based quantification of intratumoral heterogeneity for predicting the early recurrence in HCC following multiple ablation.2025Liver international : official journal of the International Association for the Study of the Liver
  49. Ethical challenges and governance of artificial intelligence in hepatocellular carcinoma management : Wan DL et al. Ethical considerations in AI for hepatocellular carcinoma.2025Medical oncology (Northwood, London, England)
  50. Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system.2025Molecular cancer免费全文
  51. OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth.2025Molecular cell
  52. The deubiquitinase USP28 maintains the expression of PPARγ and its inactivation protects mice from diet-induced MASH and hepatocarcinoma.2025Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  53. Oncolytic virus VG161 in refractory hepatocellular carcinoma.2025Nature
  54. ADSL promotes autophagy and tumor growth through fumarate-mediated Beclin1 dimethylation.2025Nature chemical biology
  55. Vision transformer-based model can optimize curative-intent treatment for patients with recurrent hepatocellular carcinoma.2025Nature communications免费全文
  56. ERK-USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and its enzyme activity-independent functions for tumor growth.2025Nature structural & molecular biology
  57. A novel cabozantinib-sulfasalazine combination targeting ferroptosis to overcome resistant immunotherapy in advanced hepatocellular carcinoma.2025Pakistan journal of pharmaceutical sciences
  58. Transferrin promotes fatty acid oxidation and liver tumor growth through PHD2-mediated PPARα hydroxylation in an iron-dependent manner.2025Proceedings of the National Academy of Sciences of the United States of America免费全文
  59. Immunomodulatory impacts of thermal and pulsed field ablation therapy on hepatocellular carcinoma associated with viral hepatitis.2025Radiologie (Heidelberg, Germany)
  60. Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma.2025Science advances免费全文
  61. Prognostic nomogram for recurrence of hepatocellular carcinoma after liver transplantation for decision making on postoperative adjuvant therapy.2025Scientific reports免费全文
  62. Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report.2025The American journal of case reports免费全文
  63. Survival outcomes after caudate lobectomy for hepatocellular carcinoma: systematic review and meta-analysis.2024ANZ journal of surgery
  64. Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study.2024Academic radiology
  65. Outcomes of liver transplantation for hepatocellular carcinoma in donation after circulatory death compared with donation after brain death: A systematic review and meta-analysis.2024Annals of hepatology
  66. Development and experimental validation of a machine learning-based disulfidptosis-related ferroptosis score for hepatocellular carcinoma.2024Apoptosis : an international journal on programmed cell death
  67. The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis.2024BMC cancer免费全文
  68. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.2024BMC cancer免费全文
  69. Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study.2024BMC gastroenterology免费全文
  70. The impact of Karnofsky performance status on prognosis of patients with hepatocellular carcinoma in liver transplantation.2024BMC gastroenterology免费全文
  71. Dynamic radiomics based on contrast-enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma.2024BMC medical imaging免费全文
  72. Economic evaluation of hepatocellular carcinoma surveillance in chronic hepatitis B patients with virological remission.2024BMC public health免费全文
  73. Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway.2024Cancer letters
  74. IRGM is a novel regulator of PD-L1 via promoting S6K1-mediated phosphorylation of YBX1 in hepatocellular carcinoma.2024Cancer letters
  75. Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis: A multi-institutional retrospective study.2024Cancer letters
  76. Predictive Prognostic Model for Hepatocellular Carcinoma Based on Seven Genes Participating in Arachidonic Acid Metabolism.2024Cancer medicine免费全文
  77. Similar usage of T-cell receptor β-chain between tumor and adjacent normal tissue in hepatocellular carcinoma.2024Cancer medicine免费全文
  78. Deep learning-based accurate diagnosis and quantitative evaluation of microvascular invasion in hepatocellular carcinoma on whole-slide histopathology images.2024Cancer medicine免费全文
  79. Clinical significance of RNA methylation in hepatocellular carcinoma.2024Cell communication and signaling : CCS免费全文
  80. Hepatitis B virus X protein promotes tumor glycolysis by downregulating lncRNA OIP5-AS1/HKDC1 in HCC.2024Cellular signalling
  81. Non-coding RNAs in hepatocellular carcinoma metastasis: Remarkable indicators and potential oncogenic mechanism.2024Computers in biology and medicine
  82. Growth differentiation factor 15: Emerging role in liver diseases.2024Cytokine
  83. Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.2024EBioMedicine免费全文
  84. Evidence of promoting effects of 6:2 Cl-PFESA on hepatocellular carcinoma proliferation in humans: An ideal alternative for PFOS in terms of environmental health?2024Environment international
  85. Environment relevant exposure of perfluorooctanoic acid accelerates the growth of hepatocellular carcinoma cells through mammalian target of rapamycin (mTOR) signal pathway.2024Environmental pollution (Barking, Essex : 1987)
  86. TRAF2 inhibits senescence in hepatocellular carcinoma cells via regulating the ROMO1/ NAD+/SIRT3/SOD2 axis.2024Free radical biology & medicine
  87. 5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction.2024Free radical biology & medicine
  88. Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma.2024Frontiers in immunology免费全文
  89. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.2024Frontiers in immunology免费全文
  90. Laparoscopic anatomical liver resection of segment 7 using a sandwich approach to the right hepatic vein (with video).2024Hepatobiliary & pancreatic diseases international : HBPD INT
  91. Concomitant hepatocellular carcinoma recurrence and mantle cell lymphoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  92. A robust genomic-based prognostic model for the assessment of cancer stemness and survival for patients with hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  93. Advanced hepatocellular carcinoma in a patient with neurofibromatosis type 1 and malignant peripheral nerve sheath tumor.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  94. Achieving laparoscopic anatomic resection for hepatocellular carcinoma by fluorescence guided positive staining of hepatic cone unit.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  95. Middle hepatic vein variation provides a safe path for anterior transection of hepatocellular carcinoma in caudate lobe.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  96. Base editing of the mutated TERT promoter inhibits liver tumor growth.2024Hepatology (Baltimore, Md.)
  97. OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma.2024Hepatology international免费全文
  98. CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis.2024Journal of experimental & clinical cancer research : CR免费全文
  99. S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function.2024Journal of experimental & clinical cancer research : CR免费全文
  100. Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis.2024Journal of hepatology
  101. Intricate effects of post-translational modifications in liver cancer: mechanisms to clinical applications.2024Journal of translational medicine免费全文
  102. The interaction between intratumoral bacteria and metabolic distortion in hepatocellular carcinoma.2024Journal of translational medicine免费全文
  103. Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy.2024Journal of viral hepatitis
  104. Hepatitis B Virus-Mediated m6A Demethylation Increases Hepatocellular Carcinoma Stemness and Immune Escape.2024Molecular cancer research : MCR免费全文
  105. Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma.2024Molecular pharmaceutics
  106. PLGA micro/nanoparticle vaccination elicits non-tumor antigen specific resident memory CD8+ T cell protection from hepatocellular carcinoma.2024Nanoscale
  107. Fructose-1,6-bisphosphatase 1 dephosphorylates and inhibits TERT for tumor suppression.2024Nature chemical biology
  108. The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation.2024Nature communications免费全文
  109. Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank.2024Nature communications免费全文
  110. Branched-Chain Amino Acids in Liver Diseases: Complexity and Controversy.2024Nutrients免费全文
  111. Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease.2024Science China. Life sciences
  112. Development of a promising PPAR signaling pathway-related prognostic prediction model for hepatocellular carcinoma.2024Scientific reports免费全文
  113. Prognostic and immune predictive roles of a novel tricarboxylic acid cycle-based model in hepatocellular carcinoma.2024Scientific reports免费全文
  114. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.2024Signal transduction and targeted therapy免费全文
  115. The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma.2024Signal transduction and targeted therapy免费全文
  116. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.2024Small (Weinheim an der Bergstrasse, Germany)
  117. A multicenter, randomized, parallel-controlled clinical trial protocol to evaluate the safety and efficacy of irreversible electroporation compared with radiofrequency ablation for the treatment of small hepatocellular carcinoma.2024World journal of surgical oncology免费全文
  118. Any Hepatic Lesion That Is Classified as LR-M Shall Not Be Ignored.2023AJR. American journal of roentgenology
  119. Effects of 3-HAA on HCC by Regulating the Heterogeneous Macrophages-A scRNA-Seq Analysis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  120. Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  121. Robotic anatomical segment 3 resection by extrahepatic Glissonian approach and Indocyanine green fluorescence navigation (with video).2023Asian journal of surgery
  122. Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation.2023BMC cancer免费全文
  123. MiR-652-3p promotes malignancy and metastasis of cancer cells via inhibiting TNRC6A in hepatocellular carcinoma.2023Biochemical and biophysical research communications
  124. Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1+ CD8+ T cells in HCC via blocking VEGFR2.2023Cancer science免费全文
  125. Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.2023Cell communication and signaling : CCS免费全文
  126. The TRAF2-p62 axis promotes proliferation and survival of liver cancer by activating mTORC1 pathway.2023Cell death and differentiation免费全文
  127. Loss of Mettl3 enhances liver tumorigenesis by inducing hepatocyte dedifferentiation and hyperproliferation.2023Cell reports
  128. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.2023Cellular signalling
  129. N6 -methyladenosine-modified circSTX6 promotes hepatocellular carcinoma progression by regulating the HNRNPD/ATF3 axis and encoding a 144 amino acid polypeptide.2023Clinical and translational medicine免费全文
  130. Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma.2023Computers in biology and medicine
  131. An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons α and λ1 in HBV infection by promoting MAVS lysosomal degradation.2023EBioMedicine免费全文
  132. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.2023EBioMedicine免费全文
  133. m6A-modification regulated circ-CCT3 acts as the sponge of miR-378a-3p to promote hepatocellular carcinoma progression.2023Epigenetics免费全文
  134. Response to Letter to the Editor regarding "Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study".2023European journal of radiology
  135. Preoperative MRI features to predict vessels that encapsulate tumor clusters and microvascular invasion in hepatocellular carcinoma.2023European journal of radiology
  136. Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study.2023European journal of radiology
  137. A new classification and regression tree algorithm: Improved diagnostic sensitivity for HCC ≤ 3.0 cm using gadoxetate disodium-enhanced MRI.2023European journal of radiology
  138. The role of enhancing capsule and modified capsule appearances in LI-RADS for diagnosing HCC ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.2023European radiology
  139. Comparative Analysis of Donor Liver Allograft Outcomes in Hepatocellular Carcinoma Patients Who Underwent Liver Transplant.2023Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  140. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?2023Frontiers in immunology免费全文
  141. Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.2023Gut免费全文
  142. Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.2023Hepatology (Baltimore, Md.)
  143. TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC.2023Hepatology communications免费全文
  144. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial.2023Hepatology communications免费全文
  145. Bioinformatics identification of a T-cell-related signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.2023IET systems biology免费全文
  146. Navigating the immunometabolic heterogeneity of B cells in murine hepatocellular carcinoma at single cell resolution.2023International immunopharmacology
  147. DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy.2023International journal of biological sciences免费全文
  148. Establishment and Validation of a Novel Risk Score for Hepatocellular Carcinoma Based on Bile Acid and Bile Salt Metabolism-Related Genes.2023International journal of molecular sciences免费全文
  149. Non-iatrogenic implantation of cutaneous metastasis from hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  150. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  151. Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  152. Single-center experience in the diagnosis and treatment of lymphoepithelioma-like hepatic carcinoma.2023Journal of cancer research and clinical oncology免费全文
  153. JNK/c-Jun pathway activation is essential for HBx-induced IL-35 elevation to promote persistent HBV infection.2023Journal of clinical laboratory analysis免费全文
  154. Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients.2023Journal of experimental & clinical cancer research : CR免费全文
  155. KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive element-binding protein 2.2023Journal of experimental & clinical cancer research : CR免费全文
  156. ST6GALNAC4 promotes hepatocellular carcinogenesis by inducing abnormal glycosylation.2023Journal of translational medicine免费全文
  157. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.2023Medicine免费全文
  158. An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma.2023Molecular carcinogenesis
  159. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function.2023Nature cell biology
  160. Nucleus-exported CLOCK acetylates PRPS to promote de novo nucleotide synthesis and liver tumour growth.2023Nature cell biology
  161. Bigelovin inhibits hepatocellular carcinoma cell growth and metastasis by regulating the MAPT-mediated Fas/FasL pathway.2023Neoplasma
  162. WDR74 serves as a novel therapeutic target by its oncogenic role in hepatocellular carcinoma.2023Pathology, research and practice
  163. Silencing of TRAF5 enhances necroptosis in hepatocellular carcinoma by inhibiting LTBR-mediated NF-κB signaling.2023PeerJ免费全文
  164. CT radiomics for noninvasively predicting NQO1 expression levels in hepatocellular carcinoma.2023PloS one免费全文
  165. Long-term outcomes of endoscopic ultrasound-guided laser ablation for liver tumors in the caudate lobe: 5 years of experience.2023Scandinavian journal of gastroenterology
  166. A novel prognostic model for hepatocellular carcinoma based on pyruvate metabolism-related genes.2023Scientific reports免费全文
  167. ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression.2023Signal transduction and targeted therapy免费全文
  168. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.2023Stem cell research & therapy免费全文
  169. Robotic versus laparoscopic liver resection in posterosuperior region: a retrospective study of consecutive cases.2023Surgical endoscopy
  170. HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis.2023Virology journal免费全文
  171. Circ_0000291 contributes to hepatocellular carcinoma tumorigenesis by binding to miR-1322 to up-regulate UBE2T.2022Annals of hepatology
  172. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.2022BMC cancer免费全文
  173. Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis.2022BMC infectious diseases免费全文
  174. Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  175. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  176. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.2022Cancer immunology, immunotherapy : CII免费全文
  177. Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma.2022Cancer medicine免费全文
  178. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.2022Cancer research
  179. Ubiquitin-specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma.2022Cancer science免费全文
  180. Drug delivery strategy in hepatocellular carcinoma therapy.2022Cell communication and signaling : CCS免费全文
  181. Exosomal hsa_circ_0004658 derived from RBPJ overexpressed-macrophages inhibits hepatocellular carcinoma progression via miR-499b-5p/JAM3.2022Cell death & disease免费全文
  182. SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.2022Cells免费全文
  183. Liver transplantation for Hepatocellular Carcinoma: A prognostic model incorporating pretransplant inflammatory cytokines.2022Cytokine
  184. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis.2022European radiology
  185. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  186. The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment.2022Frontiers in immunology免费全文
  187. Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.2022Future oncology (London, England)
  188. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.2022Gut
  189. Response to pretransplant downstaging therapy predicts patient outcome after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  190. SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  191. Ultrasound-guided in vivo porcine liver ablation with nanosecond pulsed electric fields.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  192. High nuclear ABCG1 expression is a poor predictor for hepatocellular carcinoma patient survival.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  193. Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.2022International journal of biological sciences免费全文
  194. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.2022International journal of medical sciences免费全文
  195. Expression, Prognostic Value, and Functional Mechanism of Polarity-Related Genes in Hepatocellular Carcinoma.2022International journal of molecular sciences免费全文
  196. Histological tumor micronecrosis in resected specimens after R0 hepatectomy for hepatocellular carcinomas is a factor in determining adjuvant TACE: A retrospective propensity score-matched study.2022International journal of surgery (London, England)
  197. Nanocarrier-Based Tumor-Targeting Drug Delivery Systems for Hepatocellular Carcinoma Treatments: Enhanced Therapeutic Efficacy and Reduced Drug Toxicity.2022Journal of biomedical nanotechnology
  198. Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.2022Journal of hepatology
  199. HO-1 Protects Remnant Liver against Dysfunction after Major Hepatectomy in Humans.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  200. A Nomogram Estimation for the Risk of Microvascular Invasion in Hepatocellular Carcinoma Patients Meeting the Milan Criteria.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  201. Impact of hepatitis B surface antigen positive grafts on liver transplantation in patients with benign and malignant liver disease.2022Journal of medical virology
  202. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients.2022Journal of translational medicine免费全文
  203. Association of Plasma Fibrinogen Levels on Postoperative Day 1 with 2-Year Survival of Orthotopic Liver Transplantation for HBV-Related HCC.2022Laboratory medicine
  204. Response to the clinical significance and prognostic value of 3-mercaptopyruvate sulfurtransferase in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  205. 3-Mercaptopyruvate sulfurtransferase represses tumour progression and predicts prognosis in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  206. Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation.2022Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  207. Triptolide-mediated downregulation of FLIPS in hepatoma cells occurs at the post-transcriptional level independently of proteasome-mediated pathways.2022Medical oncology (Northwood, London, England)免费全文
  208. Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth.2022Nature cell biology
  209. FUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion.2022Nature communications免费全文
  210. Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma.2022Nature metabolism
  211. Multi-Omics and Artificial Intelligence-Guided Data Integration in Chronic Liver Disease: Prospects and Challenges for Precision Medicine.2022Omics : a journal of integrative biology
  212. HFE promotes mitotic cell division through recruitment of cytokinetic abscission machinery in hepatocellular carcinoma.2022Oncogene
  213. Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity.2022Oncogene
  214. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma.2022Oncoimmunology免费全文
  215. Chlorogenic Acid, the Main Antioxidant in Coffee, Reduces Radiation-Induced Apoptosis and DNA Damage via NF-E2-Related Factor 2 (Nrf2) Activation in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  216. Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.2022Scientific reports免费全文
  217. Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease.2022Scientific reports免费全文
  218. Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma.2022Signal transduction and targeted therapy免费全文
  219. Diagnostic performance of clusterin in hepatocellular carcinoma: A meta-analysis.2022The International journal of biological markers
  220. Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis.2022Transplantation reviews (Orlando, Fla.)
  221. A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study.2021BMC cancer免费全文
  222. Cyclin-dependent kinase 19 upregulation correlates with an unfavorable prognosis in hepatocellular carcinoma.2021BMC gastroenterology免费全文
  223. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database.2021BMC gastroenterology免费全文
  224. Continuous elevation of procalcitonin in cirrhosis combined with hepatic carcinoma: a case report.2021BMC infectious diseases免费全文
  225. In silico analysis suggests disruption of interactions between HAMP from hepatocytes and SLC40A1 from macrophages in hepatocellular carcinoma.2021BMC medical genomics免费全文
  226. Differentially Expressed Long Noncoding RNAs Involved in FUBP1 Promoting Hepatocellular Carcinoma Cells Proliferation.2021BioMed research international免费全文
  227. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.2021Biochemical pharmacology
  228. MiR-9-5p promotes cell proliferation and migration of hepatocellular carcinoma by targeting CPEB3.2021Biomarkers in medicine
  229. The mechanistic, diagnostic and therapeutic novel nucleic acids for hepatocellular carcinoma emerging in past score years.2021Briefings in bioinformatics
  230. Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.2021Cancer communications (London, England)免费全文
  231. Landscape analysis of lncRNAs shows that DDX11-AS1 promotes cell-cycle progression in liver cancer through the PARP1/p53 axis.2021Cancer letters
  232. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.2021Cancer letters
  233. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.2021Cancer medicine免费全文
  234. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  235. Novel deep learning radiomics model for preoperative evaluation of hepatocellular carcinoma differentiation based on computed tomography data.2021Clinical and translational medicine免费全文
  236. Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma.2021Experimental biology and medicine (Maywood, N.J.)免费全文
  237. Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric field.2021Frontiers of medicine
  238. XIAP, commonly targeted by tumor suppressive miR-3607-5p and miR-3607-3p, promotes proliferation and inhibits apoptosis in hepatocellular carcinoma.2021Genomics
  239. Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  240. Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  241. Recent advances in immunotherapy for hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  242. Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.2021Hepatology (Baltimore, Md.)免费全文
  243. REPLY.2021Hepatology (Baltimore, Md.)
  244. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.2021International immunopharmacology
  245. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.2021International journal of biological sciences免费全文
  246. Fusion imaging-guided radiofrequency ablation for residual hepatocellular carcinoma invisible on ultrasound after transcatheter arterial chemoembolization.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  247. Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.2021Journal of cellular and molecular medicine免费全文
  248. Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1α-C/EBPα-HNF4α axis.2021Journal of cellular and molecular medicine免费全文
  249. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.2021Journal of cellular biochemistry
  250. The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma.2021Journal of cellular physiology
  251. Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma.2021Journal of clinical laboratory analysis免费全文
  252. MiR-144-3p-mediated dysregulation of EIF4G2 contributes to the development of hepatocellular carcinoma through the ERK pathway.2021Journal of experimental & clinical cancer research : CR免费全文
  253. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis.2021Journal of experimental & clinical cancer research : CR免费全文
  254. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.2021Journal of translational medicine免费全文
  255. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.2021Medical oncology (Northwood, London, England)
  256. EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation.2021Oncogene
  257. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.2021Theranostics免费全文
  258. Quantitative Ultrasound Elastography Methods in Focal Liver Lesions Including Hepatocellular Carcinoma: From Diagnosis to Prognosis.2021Ultrasound quarterly
中文论文(未计入)1
  1. [Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
它在 ClinicalTrials.gov 上的全部试验(任何状态)57
  1. TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC状态不明NCT04992143牵头方II期2021-08 启动
  2. A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer状态不明NCT05371873牵头方2021-03 启动
  3. SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT状态不明NCT04387695牵头方III期2020-04 启动
  4. Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma即将招募NCT07487402牵头方(推断)早期I期2026-03 启动
  5. Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma正在招募NCT07123545牵头方(推断)I/II期2025-08 启动
  6. A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)正在招募NCT07039201牵头方(推断)不分期2025-06 启动
  7. Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma正在招募NCT06676982牵头方(推断)I期2025-01 启动
  8. Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia正在招募NCT07359586牵头方(推断)2025-11 启动
  9. Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma正在招募NCT06995105牵头方(推断)I/II期2025-04 启动
  10. Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma正在招募NCT06461624牵头方(推断)I期2024-07 启动
  11. A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma正在招募NCT05155189牵头方(推断)I期2022-02 启动
  12. Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC Patients状态不明NCT06577272牵头方(推断)2024-09 启动
  13. Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma状态不明NCT05312216牵头方(推断)II期2023-04 启动
  14. Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients已完成NCT05213221牵头方(推断)II期2022-03 启动
  15. HCC Staging Modified by Tumor Micronecrosis已完成NCT05739110牵头方(推断)2022-07 启动
  16. Prognostic Models for HCC Based on Tumor Micronecrosis状态不明NCT05837065牵头方(推断)2022-09 启动
  17. Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma进行中,不再招募NCT04756648牵头方(推断)I期2021-03 启动
  18. IMC001 for Clinical Research on Advanced Digestive System Malignancies状态不明NCT05028933牵头方(推断)I期2021-09 启动
  19. SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma已完成NCT04930315牵头方(推断)II期2021-09 启动
  20. A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection状态不明NCT04981665牵头方(推断)II期2021-11 启动
  21. Perioperative Therapy for Hepatocellular Carcinoma已终止NCT04653389牵头方(推断)II期2020-12 启动
  22. Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients已完成NCT04418401牵头方(推断)I期2020-06 启动
  23. AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma状态不明NCT04368182牵头方(推断)I期2020-04 启动
  24. Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas已完成NCT05352204牵头方(推断)2020-04 启动
  25. Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation状态不明NCT04232722牵头方(推断)II期2020-01 启动
  26. Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC状态不明NCT04174781牵头方(推断)II期2019-11 启动
  27. Survival Analysis: TACE vs. Combination Therapy in HCC已完成NCT06261138牵头方(推断)2019-02 启动
  28. Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant状态不明NCT04035876牵头方(推断)I/II期2019-07 启动
  29. 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3已完成NCT03980288牵头方(推断)I期2019-07 启动
  30. A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence已终止NCT03945799牵头方(推断)I/II期2019-04 启动
  31. Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation已撤回NCT02580253牵头方(推断)II期2017-11 启动
  32. Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1已撤回NCT02129322牵头方(推断)II期2015-07 启动
  33. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC即将招募NCT07596134研究中心不分期2026-10 启动
  34. JMT106 Injection in the Treatment of Advanced Solid Tumors正在招募NCT07275073研究中心I期2025-09 启动
  35. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  36. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  37. A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)进行中,不再招募NCT06590246研究中心I/II期2024-09 启动
  38. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  39. A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma已完成NCT04728321研究中心II期2021-01 启动
  40. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  41. Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer状态不明NCT04806464研究中心I期2021-03 启动
  42. A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma已终止NCT04635527研究中心I期2020-12 启动
  43. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  44. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  45. Chimeric Antigen Receptor T Cells Targeting Glypican-3已完成NCT03884751研究中心I期2019-08 启动
  46. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  47. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects已终止NCT03591965研究中心II期2018-08 启动
  48. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  49. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  50. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  51. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  52. Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge状态不明NCT03277716研究中心不分期2017-12 启动
  53. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma已完成NCT03113955研究中心不分期2017-10 启动
  54. A Study to Evaluate SHR-1210 in Subjects With Advanced HCC已完成NCT02989922研究中心II期2016-11 启动
  55. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  56. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC状态不明NCT03313596研究中心III期2013-03 启动
  57. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 65 篇,占 0.7%。

牵头论文
65
2021–2025 年
牵头试验
24
任何状态,ClinicalTrials.gov
牵头的开放试验
14
正在或即将招募
作为研究中心的开放试验
14
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 121220222023: 9920232024: 121220242025: 19192025

杭州有 9 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 28

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer
    分期
    未注明
    开始
    2026-04
    登记号
    NCT07525765

    年龄 18 岁 至 90 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 正在招募
    Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07104214

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  3. 正在招募
    The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
    分期
    未注明
    开始
    2025-10
    登记号
    NCT07139418

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  4. 正在招募
    Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
    分期
    不分期
    开始
    2025-10
    登记号
    NCT07175155

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 2 家列出的医院为研究中心北京、台州、杭州

  5. 正在招募
    High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
    分期
    不分期
    开始
    2025-12
    登记号
    NCT07307560

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  6. 正在招募
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07359586

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  7. 正在招募
    Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
    分期
    未注明
    开始
    2024-05
    登记号
    NCT06728878

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  8. 正在招募
    Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
    分期
    未注明
    开始
    2024-05
    登记号
    NCT06728891

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  9. 正在招募
    Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
    分期
    未注明
    开始
    2024-05
    登记号
    NCT06736847

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  10. 正在招募
    Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
    分期
    I期
    开始
    2024-07
    登记号
    NCT06821048

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  11. 正在招募
    CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
    分期
    早期I期
    开始
    2024-12
    登记号
    NCT06937567

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  12. 即将招募
    18F-FAPI PET/CT and MRI in Gastric Cancer
    分期
    未注明
    开始
    2026-05
    登记号
    NCT07510867

    年龄 20 岁 至 80 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  13. 即将招募
    Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
    分期
    II期
    开始
    2026-06
    登记号
    NCT07621562

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  14. 即将招募
    High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07791979

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  15. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  16. 正在招募
    IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
    分期
    II期
    开始
    2026-04
    登记号
    NCT07483554

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

  17. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  18. 正在招募
    COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
    分期
    不分期
    开始
    2025-04
    登记号
    NCT06796764

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心杭州

  19. 正在招募
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    分期
    III期
    开始
    2025-05
    登记号
    NCT06901531

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、西宁、郑州

  20. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  21. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、洛阳、石家庄、福州、蚌埠、西宁、郑州、重庆、银川、长春、长沙、青岛

  22. 正在招募
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    分期
    I期
    开始
    2023-08
    登记号
    NCT06043466

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心杭州

  23. 正在招募
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    分期
    不分期
    开始
    2023-12
    登记号
    NCT06081647

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院;另有 7 家列出的医院为研究中心上海、南京、南昌、杭州、济南

  24. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  25. 正在招募
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    分期
    I期
    开始
    2022-06
    登记号
    NCT05365581

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、杭州、武汉、郑州

  26. 即将招募
    SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
    分期
    I期
    开始
    2026-12
    登记号
    NCT07903857

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

  27. 即将招募
    Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions
    分期
    不分期
    开始
    2026-11
    登记号
    NCT07904260

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

  28. 即将招募
    Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
    分期
    II期
    开始
    2023-07
    登记号
    NCT05970627

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心宁波、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期化疗与综合治疗影像与人工智能
论文中的科室肿瘤内科消化/肝病科病理/检验科影像/核医学科
牵头的论文65
  1. Helicobacter pylori-naïve status is associated with poor prognosis and aggressive pathological features in undifferentiated-type gastric cancer: a multi-center retrospective cohort study.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  2. Blood Biomarker-Based Predictive Indicator for Liver Metastasis in Alpha-Fetoprotein-Producing Gastric Cancer and Multi-Omics Tumor Microenvironment Insights.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Entropy-Driven Nucleic Acid Amplifier Based on Spatial Confinement as a "Booster" for Detection of Extracellular Vesicle MicroRNAs to Diagnose Gastric Cancer and Monitor Therapeutic Response.2025Analytical chemistry
  4. Prognostic Value of CD133 and SOX2 Expression After Neoadjuvant Chemotherapy in Patients With Locally Advanced Gastric Cancer.2025Asia-Pacific journal of clinical oncology免费全文
  5. Deciphering mismatch repair protein expression variability in gastric cancer: clinical and prognostic implications.2025BMC cancer免费全文
  6. The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.2025BMC cancerRCT免费全文
  7. Prediction of pathological response to neoadjuvant immunochemotherapy with baseline and post-treatment 18F-FDG PET imaging biomarkers in patients with locally advanced gastric cancer.2025BMC cancer免费全文
  8. Relationship between the degree of Helicobacter pylori infection and miR-155 and miR-543 expression levels in gastric cancer.2025BMC gastroenterology免费全文
  9. The clinical benefits of [18F]AlF-NOTA-octreotide PET/CT in staging and restaging patients with gastroenteropancreatic neuroendocrine neoplasms: comparison of [18F]FDG PET/CT.2025BMC medical imaging免费全文
  10. CircSRPK1 mediated by the exon junction complex promotes gastric cancer progression by interacting with hnRNP A2B1 to regulate RON mRNA alternative splicing.2025Cancer letters
  11. FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  12. S100A8/A9-MCAM signaling promotes gastric cancer cell progression via ERK-c-Jun activation.2025In vitro cellular & developmental biology. Animal免费全文
  13. PD-L1 splice variant-driven soluble PD-L1 secretion promotes immune evasion in gastric cancer.2025International journal of biological macromolecules
  14. TGF-βI/FERMT2/COL6A1 Reciprocal Loop Drives Tumor-Stroma Crosstalk and Promotes Peritoneal Metastasis in Gastric Cancer.2025International journal of biological sciences免费全文
  15. High Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.2025Journal of cachexia, sarcopenia and muscleRCT免费全文
  16. AC129507.1 is a ferroptosis-related target identified by a novel mitochondria-related lncRNA signature that is involved in the tumor immune microenvironment in gastric cancer.2025Journal of translational medicine免费全文
  17. Microbial and Metabolomic Variations Correlated With Gastric Cancer Subtypes and Prognosis.2025MicrobiologyOpen免费全文
  18. Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer.2025Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  19. TPOAb indicates neuroendocrine tumor in autoimmune gastritis: A retrospective study of 91 patients.2025The American journal of the medical sciences
  20. Effect of thoracic size on postoperative outcomes in transabdominal gastrectomy for Siewert type II/III adenocarcinoma of the esophagogastric junction.2025World journal of surgical oncology免费全文
  21. Examining the role of resilience in the relationship between social support and fear of recurrence among patients with gastric cancer on chemotherapy: a cross-sectional study in Jiangsu, China.2024BMJ open免费全文
  22. MEF2D facilitates liver metastasis of gastric cancer cells through directly inducing H1X under IL-13 stimulation.2024Cancer letters
  23. Association of metabolic syndrome and frailty with postoperative complications in older gastric cancer patients: A body composition perspective.2024Cancer medicine免费全文
  24. Downregulation of malic enzyme 3 facilitates progression of gastric carcinoma via regulating intracellular oxidative stress and hypoxia-inducible factor-1α stabilization.2024Cellular and molecular life sciences : CMLS免费全文
  25. Stem cell landscape aids in tumor microenvironment identification and selection of therapeutic agents in gastric cancer.2024Cellular signalling
  26. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  27. DNA hypomethylation of INHBA promotes tumor progression and predicts prognosis and immune status of gastric cancer.2024Hereditas免费全文
  28. MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation.2024Journal of experimental & clinical cancer research : CR免费全文
  29. KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner.2024Journal of translational medicine免费全文
  30. Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis.2024Scandinavian journal of gastroenterology
  31. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.2024Scientific reports免费全文
  32. Development and evaluation of the Newstage system: integrating tumor regression grade and lymph node status for improved prognostication in neoadjuvant treatment of gastric cancer.2024World journal of surgical oncology免费全文
  33. Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  34. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.2023Annals of surgical oncology免费全文
  35. The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer.2023Cancer medicine免费全文
  36. Prognostic effects of the gastric mucosal microbiota in gastric cancer.2023Cancer science免费全文
  37. Therapeutic effects and safety of apatinib mesylate on patients with gastric carcinoma peritoneal metastasis in SOX scheme.2023European review for medical and pharmacological sciences
  38. Proteomic profiling of gastric cancer with peritoneal metastasis identifies a protein signature associated with immune microenvironment and patient outcome.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  39. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.2023Medicine
  40. A new protective gel to facilitate ulcer healing in artificial ulcers following oesophageal endoscopic submucosal dissection: a multicentre, randomized trial.2023Scientific reportsRCT免费全文
  41. Aldo-keto Reductase 1B10 Restrains Cell Migration, Invasion, and Adhesion of Gastric Cancer via Regulating Integrin Subunit Alpha 5.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  42. A multicenter study on the preoperative prediction of gastric cancer microsatellite instability status based on computed tomography radiomics.2022Abdominal radiology (New York)
  43. Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing.2022Clinical and translational medicine免费全文
  44. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.2022Frontiers in immunology免费全文
  45. Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers.2022Frontiers in immunology免费全文
  46. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.2022Frontiers in immunology免费全文
  47. Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.2022International journal of biological sciences免费全文
  48. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.2022JAMA network openRCT免费全文
  49. Comparison of Clinical Efficacy Between Laparoscopic and Open Distal Gastrectomy in the Treatment of Gastric Carcinoma: A Meta-Analysis.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  50. Lymphoepithelioma-like Carcinoma of the Stomach: A Case Successfully Treated with Chemotherapy.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  51. Microbiota and metabolites alterations in proximal and distal gastric cancer patients.2022Journal of translational medicine免费全文
  52. Host miRNAs-microbiota interactions in gastric cancer.2022Journal of translational medicine免费全文
  53. Circular RNAs in endometrial carcinoma (Review).2022Oncology reports免费全文
  54. Confocal laser endomicroscopy under propofol-based sedation for early gastric cancer and pre-cancerous lesions is associated with better diagnostic accuracy: a retrospective cohort study in China.2021BMC anesthesiology免费全文
  55. CT differentiation of gastric ectopic pancreas from gastric stromal tumor.2021BMC gastroenterology免费全文
  56. The impact of a prior malignancy on outcomes in gastric cancer patients.2021Cancer medicine免费全文
  57. Impact of prior cancer history on survival of patients with gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  58. Comment on: "Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric cancer, 2021 Aug 11" by Iwatsuki et al.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  59. Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  60. Comment on: "Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study. Gastric cancer, 2021 Aug 5" by Kim et al.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  61. A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  62. Global Patterns and Trends in Gastric Cancer Incidence Rates (1988-2012) and Predictions to 2030.2021Gastroenterology
  63. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.2021Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  64. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.2021Nature communications免费全文
  65. Carcinosarcoma of the stomach with alpha-fetoprotein-producing hepatoid adenocarcinoma: an unexpected combination of two rare subtypes of gastric cancer in one tumor.2021The Journal of international medical research免费全文
中文论文(未计入)2
  1. [Amphicrine carcinoma of the stomach: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Concept and clinicopathological features of gastrointestinal very well differentiated adenocarcinoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)63
  1. Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer即将招募NCT07621562牵头方II期2026-06 启动
  2. AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer正在招募NCT07525765牵头方2026-04 启动
  3. 18F-FAPI PET/CT and MRI in Gastric Cancer即将招募NCT07510867牵头方2026-05 启动
  4. Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.状态不明NCT04778839牵头方I期2021-03 启动
  5. The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.状态不明NCT04065282牵头方II期2019-08 启动
  6. High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease即将招募NCT07791979牵头方(推断)不分期2026-08 启动
  7. Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy正在招募NCT07104214牵头方(推断)2025-08 启动
  8. Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients正在招募NCT07175155牵头方(推断)不分期2025-10 启动
  9. Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia正在招募NCT07359586牵头方(推断)2025-11 启动
  10. The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy正在招募NCT07139418牵头方(推断)2025-10 启动
  11. High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients正在招募NCT07307560牵头方(推断)不分期2025-12 启动
  12. Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy正在招募NCT06728891牵头方(推断)2024-05 启动
  13. Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors正在招募NCT06821048牵头方(推断)I期2024-07 启动
  14. CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors正在招募NCT06937567牵头方(推断)早期I期2024-12 启动
  15. Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer正在招募NCT06736847牵头方(推断)2024-05 启动
  16. Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer正在招募NCT06728878牵头方(推断)2024-05 启动
  17. Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients已完成NCT06812403牵头方(推断)II期2025-02 启动
  18. COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients已完成NCT06804876牵头方(推断)II期2025-02 启动
  19. High-flow Nasal Cannula Oxygenation in Sedated Endoscopy for High-risk Obstructive Sleep Apnea Patients已完成NCT07155330牵头方(推断)不分期2025-09 启动
  20. Validation of a Model for Predicting Duodenal Stump Leakage After Gastrectomy进行中,不再招募NCT06807372牵头方(推断)2024-09 启动
  21. In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer状态不明NCT05842187牵头方(推断)不分期2023-03 启动
  22. A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors已完成NCT05396300牵头方(推断)I期2022-05 启动
  23. IMC001 for Clinical Research on Advanced Digestive System Malignancies状态不明NCT05028933牵头方(推断)I期2021-09 启动
  24. TAS-102 and Anlotinib in ≥3 Lines mGC状态不明NCT05029102牵头方(推断)II期2021-09 启动
  25. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  26. IBI343 in Combination Therapy for Advanced Malignant Solid Tumors正在招募NCT07483554研究中心II期2026-04 启动
  27. Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions即将招募NCT07904260研究中心不分期2026-11 启动
  28. SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors即将招募NCT07903857研究中心I期2026-12 启动
  29. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  30. COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial正在招募NCT06796764研究中心不分期2025-04 启动
  31. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer正在招募NCT06901531研究中心III期2025-05 启动
  32. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  33. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  34. Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma即将招募NCT05970627研究中心II期2023-07 启动
  35. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure正在招募NCT06081647研究中心不分期2023-12 启动
  36. A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors正在招募NCT06043466研究中心I期2023-08 启动
  37. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  38. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer正在招募NCT05365581研究中心I期2022-06 启动
  39. Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration状态不明NCT06396143研究中心2024-07 启动
  40. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  41. Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma进行中,不再招募NCT05715931研究中心II期2023-05 启动
  42. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  43. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  44. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  45. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  46. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)已终止NCT04933227研究中心II期2021-08 启动
  47. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  48. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  49. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  50. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors已完成NCT04400383研究中心I期2020-06 启动
  51. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  52. Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)状态不明NCT04515615研究中心II期2020-09 启动
  53. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment已终止NCT04178460研究中心I期2020-02 启动
  54. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  55. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  56. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer已完成NCT04053205研究中心I/II期2019-11 启动
  57. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  58. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  59. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  60. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  61. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  62. Study of Metatinib Tromethamine Tablet状态不明NCT02650375研究中心I期2015-10 启动
  63. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma已完成NCT01364376研究中心不分期2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.4%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 2220232024: 1120242025: 112025

杭州有 20 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Osteopontin derived from hypoxia-induced M2 macrophages promotes osteosarcoma progression through modulation of EGR3/ISG15 signaling and RIG-I expression.2025Journal of translational medicine
  2. PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes.2024International journal of biological sciences
  3. A risk score model based on endoplasmic reticulum stress related genes for predicting prognostic value of osteosarcoma.2023BMC musculoskeletal disorders
  4. Development of a novel vasculogenic mimicry-associated gene signature for the prognostic assessment of osteosarcoma patients.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. LINC00313 facilitates osteosarcoma carcinogenesis and metastasis through enhancing EZH2 mRNA stability and EZH2-mediated silence of PTEN expression.2022Cellular and molecular life sciences : CMLS
  6. Circular RNA ROCK1, a novel circRNA, suppresses osteosarcoma proliferation and migration via altering the miR-532-5p/PTEN axis.2022Experimental & molecular medicine
  7. MCAM is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration.2022Journal of clinical laboratory analysis
  8. Primary fibroblastic osteosarcoma of sternum: A case report.2022Medicine
中文论文(未计入)1
  1. [Adamantinoma-like Ewing sarcoma of duodenal ameoblastoma with EWSR1::ERG gene fusion: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
早期论文(2016–2020 年)4
  1. Nomograms for predicting overall survival and cancer-specific survival of chondroblastic osteosarcoma patients.2020Journal of surgical oncology
  2. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.2019Journal of cellular biochemistry
  3. Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Proliferation and Metastasis of Osteosarcoma Cells by Targeting c-Met and SOX4 via miR-34a/c-5p and miR-449a/b.2019Medical science monitor : international medical journal of experimental and clinical research
  4. Nano-pulse stimulation (NPS) ablate tumors and inhibit lung metastasis on both canine spontaneous osteosarcoma and murine transplanted hepatocellular carcinoma with high metastatic potential.2017Oncotarget

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 1.7%。

牵头论文
9
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 1120232024: 2220242025: 112025

杭州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
    分期
    II期
    开始
    2021-09
    登记号
    NCT04933669

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科普外/肝胆胰外科肿瘤内科影像/核医学科
牵头的论文9
  1. Clinicopathological features and treatment of gastrointestinal schwannomas.2025World journal of gastroenterology
  2. Pancreatic giant malignancy simulating a gastrointestinal stromal tumor.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  3. Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis.2024Scandinavian journal of gastroenterology
  4. Reassessment of the recurrence risk of primary gastrointestinal stromal tumour after complete resection.2023Scandinavian journal of gastroenterology
  5. Elevated preoperative controlling nutritional status (CONUT) scores as a predictor of postoperative recurrence in gastrointestinal stromal tumors.2022Journal of surgical oncology
  6. Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review.2022Medicine
  7. Endoscopic treatment can be a viable therapeutic option for esophageal gastrointestinal stromal tumors.2022Scandinavian journal of gastroenterology
  8. CT differentiation of gastric ectopic pancreas from gastric stromal tumor.2021BMC gastroenterology免费全文
  9. Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
早期论文(2016–2020 年)7
  1. Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors.2020Clinical and translational gastroenterology
  2. Gastrointestinal stromal tumour with an unusual presentation as a huge prostatic mass: a case report.2019ANZ journal of surgery
  3. Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.2019Medicine
  4. Robot-assisted laparoscopic surgery for abdominal metastatic melanoma mimicking a gastrointestinal stromal tumor: A case report and review of the literature.2018Medicine
  5. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.2018Scandinavian journal of gastroenterology
  6. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.2016Oncology reports
  7. Comparison of endoscopic submucosal dissection and surgery for the treatment of gastric submucosal tumors originating from the muscularis propria layer: a single-center study (with video).2016Surgical endoscopy
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors正在招募NCT04933669牵头方II期2021-09 启动
  2. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  3. A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor已完成NCT04254939研究中心I/II期2019-08 启动
  4. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.4%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

杭州有 8 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06852807

    年龄 未注明 至 18 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科普外/肝胆胰外科
牵头的论文5
  1. Comprehensive analysis of [18F]MFBG biodistribution normal patterns and variability in pediatric patients with neuroblastoma.2026European journal of nuclear medicine and molecular imaging
  2. [18F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.2026European journal of nuclear medicine and molecular imaging
  3. 18F-meta-fluorobenzylguanidine as a New PET Tracer in Imaging Neuroblastoma.2026PET clinics
  4. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.2023The Journal of biological chemistry
  5. Upregulation of miR-499a-5p Decreases Cerebral Ischemia/Reperfusion Injury by Targeting PDCD4.2022Cellular and molecular neurobiology
早期论文(2016–2020 年)1
  1. Microarray analysis of lncRNA expression in rabies virus infected human neuroblastoma cells.2019Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma正在招募NCT06852807牵头方2025-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 6 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科
中文论文(未计入)1
  1. [Adamantinoma-like Ewing sarcoma of duodenal ameoblastoma with EWSR1::ERG gene fusion: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 55 篇,占 3.3%。

牵头论文
55
2021–2025 年
牵头试验
14
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
19
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 141420222023: 131320232024: 7720242025: 10102025

杭州有 9 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 25

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    分期
    I期
    开始
    2024-10
    登记号
    NCT06644118

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 正在招募
    Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
    分期
    未注明
    开始
    2023-12
    登记号
    NCT06463717

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  3. 正在招募
    APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2022-05
    登记号
    NCT04657861

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  4. 正在招募
    CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
    分期
    早期I期
    开始
    2021-11
    登记号
    NCT04662294

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  5. 即将招募
    A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
    分期
    早期I期
    开始
    2021-01
    登记号
    NCT04670055

    年龄 30 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  6. 即将招募
    A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
    分期
    早期I期
    开始
    2020-12
    登记号
    NCT04541368

    年龄 30 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  7. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  8. 正在招募
    A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
    分期
    I期
    开始
    2026-02
    登记号
    NCT07409246

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心天津、杭州

  9. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  10. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  11. 正在招募
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2026-03
    登记号
    NCT07529782

    年龄 未注明 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州

  12. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  13. 正在招募
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-05
    登记号
    NCT06375044

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州

  14. 正在招募
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
    分期
    III期
    开始
    2024-08
    登记号
    NCT06520176

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:宁波大学附属人民医院;另有 6 家列出的医院为研究中心台州、宁波、杭州、温州

  15. 正在招募
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-06
    登记号
    NCT06574568

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州

  16. 正在招募
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05565807

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州

  17. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、芜湖、苏州、西安、贵阳、郑州、长春、青岛

  18. 正在招募
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    分期
    IV期
    开始
    2023-10
    登记号
    NCT06057402

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、广州、杭州、济南

  19. 正在招募
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06182696

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、南京、杭州、武汉

  20. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

  21. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  22. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  23. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  24. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

  25. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与耐药CAR-T 与细胞治疗诊断、微小残留病与危险分层
论文中的科室肿瘤内科影像/核医学科
牵头的论文55
  1. Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy.2026Bone marrow transplantation
  2. Evaluation of iMS-IP assay for the detection and typing of monoclonal immunoglobulins.2026Clinica chimica acta; international journal of clinical chemistry
  3. Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5/8-CXCR2 axis.2026Haematologica免费全文
  4. MRD contamination in peripheral blood autologous stem cell grafts: implications for relapse and prognosis in multiple myeloma.2026Leukemia & lymphoma
  5. The Ratio of Serum Urea Nitrogen to Albumin Is a Better Predictor of Overall Survival in Multiple Myeloma Patients than Urea Nitrogen Alone.2025Acta haematologica免费全文
  6. Serum ferritin can serve as a biomarker for the prognosis and increased the prognostic predictive value of ISS/RISS in multiple myeloma patients.2025Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  7. Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study.2025Bone marrow transplantation免费全文
  8. Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.2025Cancer免费全文
  9. Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells.2025Chinese medical journal免费全文
  10. N6-methyladenosine-mediated upregulation of H19 promotes resistance to bortezomib by modulating the miR-184/CARM1 axis in multiple myeloma.2025Clinical and experimental medicine免费全文
  11. Determining the factors affecting bortezomib's adverse events in the treatment of newly diagnosed multiple myeloma.2025Hematology (Amsterdam, Netherlands)
  12. Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.2025International journal of hematology
  13. Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2025Journal for immunotherapy of cancer免费全文
  14. Di-(2-ethylhexyl) phthalate (DEHP) and its metabolite promote multiple myeloma progression and bortezomib resistance.2025Journal of hazardous materials
  15. The development and validation of a liquid chromatography tandem mass spectrometry method for the quantification of selinexor and its application in Chinese multiple myeloma patients.2024Analytical methods : advancing methods and applications
  16. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.2024Biomolecules免费全文
  17. Disruption of DNA-PKcs-mediated cGAS retention on damaged chromatin potentiates DNA damage-inducing agent-induced anti-multiple myeloma activity.2024British journal of cancer免费全文
  18. The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients.2024Cancer biology & therapy免费全文
  19. Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.2024Cancer medicine免费全文
  20. Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab.2024Cancer science免费全文
  21. Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neurotoxicity.2023Archives of toxicology
  23. TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy.2023Blood advances免费全文
  24. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy.2023Bone marrow transplantation
  25. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.2023British journal of haematology
  26. Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma.2023Cancer immunology, immunotherapy : CII免费全文
  27. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.2023Cytotherapy
  28. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.2023Frontiers in immunology免费全文
  29. Calcium silicate/bortezomib combinatory therapy for multiple myeloma.2023Journal of materials chemistry. B
  30. The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.2023Leukemia免费全文
  31. Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma.2023Leukemia & lymphoma
  32. New diagnostic strategy for multiple myeloma: A review.2023Medicine免费全文
  33. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.2023The Lancet. Haematology
  34. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.2023Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  35. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).2022Annals of hematology免费全文
  36. Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma.2022Cancer research免费全文
  37. NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma.2022Cell death & disease免费全文
  38. Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.2022Clinical epigenetics免费全文
  39. Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma.2022Current oncology (Toronto, Ont.)免费全文
  40. A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials.2022Haematologica
  41. High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma.2022Journal of Zhejiang University. Science. B免费全文
  42. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.2022Nature communications免费全文
  43. RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways.2022Oncogene免费全文
  44. Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis.2022Oncoimmunology免费全文
  45. Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients.2022Scientific reports免费全文
  46. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences免费全文
  47. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences免费全文
  48. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences免费全文
  49. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019.2021BMC cancer免费全文
  50. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  51. Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma.2021Blood cancer journal免费全文
  52. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial.2021Bone marrow transplantation
  53. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.2021Clinical cancer research : an official journal of the American Association for Cancer Research免费全文
  54. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels.2021Cytokine
  55. Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.2021Molecular therapy : the journal of the American Society of Gene Therapy免费全文
中文论文(未计入)3
  1. [Advances for treatment of relapsed or refractory multiple myeloma: interpretation of guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  2. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest.2023Journal of Zhejiang University. Science. B免费全文
  3. [Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].2022Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)69
  1. Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not正在招募NCT06463717牵头方2023-12 启动
  2. B Cell Maturation Antigen(BMCA)-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma状态不明NCT03931421牵头方II期2019-07 启动
  3. Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma状态不明NCT03716856牵头方I期2018-03 启动
  4. A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)正在招募NCT06644118牵头方(推断)I期2024-10 启动
  5. APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma正在招募NCT04657861牵头方(推断)早期I期2022-05 启动
  6. CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases正在招募NCT04662294牵头方(推断)早期I期2021-11 启动
  7. A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma即将招募NCT04670055牵头方(推断)早期I期2021-01 启动
  8. A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy即将招募NCT04541368牵头方(推断)早期I期2020-12 启动
  9. A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma状态不明NCT06084962牵头方(推断)I期2023-10 启动
  10. AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma状态不明NCT05740891牵头方(推断)I期2023-03 启动
  11. A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma状态不明NCT05712083牵头方(推断)II期2023-01 启动
  12. A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma状态不明NCT05430945牵头方(推断)早期I期2022-06 启动
  13. A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma状态不明NCT05016778牵头方(推断)早期I期2021-06 启动
  14. CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies状态不明NCT04603872牵头方(推断)早期I期2020-11 启动
  15. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  16. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  17. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT07529782研究中心I期2026-03 启动
  18. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  19. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  20. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)正在招募NCT07409246研究中心I期2026-02 启动
  21. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  22. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06375044研究中心I期2024-05 启动
  23. Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients正在招募NCT06520176研究中心III期2024-08 启动
  24. A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06574568研究中心I期2024-06 启动
  25. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  26. OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM正在招募NCT06182696研究中心I/II期2023-10 启动
  27. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)正在招募NCT06057402研究中心IV期2023-10 启动
  28. Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma正在招募NCT05565807研究中心I/II期2023-02 启动
  29. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  30. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  31. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  32. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  33. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  34. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  35. GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma进行中,不再招募NCT06566547研究中心II期2024-08 启动
  36. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  37. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  38. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma状态不明NCT05719701研究中心I/II期2023-03 启动
  39. Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies状态不明NCT05536154研究中心不分期2022-11 启动
  40. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  41. Phase I Trial of GR1803 Injection in Patients With RRMM已完成NCT07102706研究中心I/II期2022-05 启动
  42. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  43. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma状态不明NCT05236621研究中心III期2021-01 启动
  44. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  45. Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma状态不明NCT05346198研究中心I期2021-03 启动
  46. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  47. A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma已完成NCT05011097研究中心I期2021-07 启动
  48. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma已终止NCT04735575研究中心I/II期2021-05 启动
  49. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma状态不明NCT04674514研究中心I/II期2021-04 启动
  50. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  51. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  52. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT04557098研究中心II期2020-09 启动
  53. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  54. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动
  55. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)已完成NCT03748953研究中心III期2019-01 启动
  56. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  57. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  58. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  59. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  60. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  61. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  62. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  63. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  64. An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants已终止NCT02761187研究中心2016-07 启动
  65. Ixazomib Rollover Study已完成NCT02924272研究中心II期2016-12 启动
  66. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)已完成NCT02312258研究中心III期2015-04 启动
  67. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  68. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year已完成NCT02348528研究中心II期2012-09 启动
  69. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma已完成NCT01593410研究中心II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.2%。

牵头论文
5
2021–2025 年
牵头试验
25
任何状态,ClinicalTrials.gov
牵头的开放试验
13
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025

杭州有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 14

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    分期
    I期
    开始
    2026-01
    登记号
    NCT07246707

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 正在招募
    Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
    分期
    早期I期
    开始
    2026-02
    登记号
    NCT07429461

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  3. 正在招募
    Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
    分期
    早期I期
    开始
    2025-01
    登记号
    NCT06793241

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  4. 正在招募
    Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
    分期
    不分期
    开始
    2025-02
    登记号
    NCT07003737

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  5. 正在招募
    Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
    分期
    II期
    开始
    2025-08
    登记号
    NCT07105579

    年龄 14 岁 至 65 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  6. 正在招募
    CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
    分期
    早期I期
    开始
    2024-05
    登记号
    NCT06346912

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  7. 正在招募
    Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
    分期
    II期
    开始
    2024-08
    登记号
    NCT06554626

    年龄 40 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  8. 正在招募
    Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
    分期
    II期
    开始
    2024-10
    登记号
    NCT06742515

    年龄 15 岁 至 59 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  9. 正在招募
    Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
    分期
    II期
    开始
    2024-12
    登记号
    NCT06754267

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  10. 正在招募
    A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
    分期
    早期I期
    开始
    2020-01
    登记号
    NCT04227015

    年龄 3 岁 至 70 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  11. 即将招募
    Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
    分期
    II期
    开始
    2025-03
    登记号
    NCT06861348

    年龄 14 岁 至 65 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  12. 即将招募
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
    分期
    不分期
    开始
    2025-03
    登记号
    NCT06902025

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  13. 即将招募
    CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
    分期
    早期I期
    开始
    2020-11
    登记号
    NCT04609241

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  14. 正在招募
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06580301

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、广州、徐州、杭州、贵阳、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学微小残留病与复发儿童
牵头的论文5
  1. Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.2026British journal of haematology
  2. Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia.2026Clinical lymphoma, myeloma & leukemia
  3. Safety and efficacy of CD19-targeted CAR-T-cell therapy for patients with relapsed or refractory TCF3-PBX1 fusion gene-positive B-ALL.2025Hematology (Amsterdam, Netherlands)
  4. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.2023Annals of hematology
  5. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.2021Clinical cancer research : an official journal of the American Association for Cancer Research
中文论文(未计入)1
  1. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)29
  1. Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT即将招募NCT06861348牵头方II期2025-03 启动
  2. Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation正在招募NCT07003737牵头方不分期2025-02 启动
  3. Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia正在招募NCT07105579牵头方II期2025-08 启动
  4. Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL正在招募NCT06554626牵头方II期2024-08 启动
  5. Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL正在招募NCT06754267牵头方II期2024-12 启动
  6. Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL正在招募NCT06742515牵头方II期2024-10 启动
  7. KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia正在招募NCT07246707牵头方(推断)I期2026-01 启动
  8. Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia正在招募NCT07429461牵头方(推断)早期I期2026-02 启动
  9. JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia即将招募NCT06902025牵头方(推断)不分期2025-03 启动
  10. Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia正在招募NCT06793241牵头方(推断)早期I期2025-01 启动
  11. CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL正在招募NCT06346912牵头方(推断)早期I期2024-05 启动
  12. CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma即将招募NCT04609241牵头方(推断)早期I期2020-11 启动
  13. A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy正在招募NCT04227015牵头方(推断)早期I期2020-01 启动
  14. Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia进行中,不再招募NCT07199855牵头方(推断)II期2025-06 启动
  15. Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL已完成NCT05350787牵头方(推断)I期2022-03 启动
  16. Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL状态不明NCT05350852牵头方(推断)I期2022-03 启动
  17. Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL已完成NCT04788472牵头方(推断)II期2021-03 启动
  18. Natural Killer (NK) Cell Therapy for B-Cell Malignancies状态不明NCT05379647牵头方(推断)I期2021-11 启动
  19. Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL状态不明NCT04740203牵头方(推断)I/II期2021-01 启动
  20. A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy状态不明NCT04226989牵头方(推断)早期I期2020-02 启动
  21. A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies状态不明NCT04532203牵头方(推断)早期I期2020-11 启动
  22. A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL状态不明NCT04532268牵头方(推断)早期I期2020-08 启动
  23. CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies状态不明NCT04603872牵头方(推断)早期I期2020-11 启动
  24. A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies状态不明NCT04532281牵头方(推断)早期I期2020-11 启动
  25. A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies已完成NCT04689204牵头方(推断)早期I期2020-12 启动
  26. Study of YK012 in B-cell Acute Lymphoblastic Leukemia正在招募NCT06580301研究中心I/II期2024-09 启动
  27. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL进行中,不再招募NCT04521231研究中心I/II期2021-01 启动
  28. Safety and Efficacy Evaluation of CD19-UCART已暂停NCT03229876研究中心不分期2019-06 启动
  29. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

杭州有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
    分期
    早期I期
    开始
    2024-10
    登记号
    NCT06633328

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 即将招募
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07552506

    年龄 14 岁 至 50 岁;仅女性(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院;另有 3 家列出的医院为研究中心杭州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 14 篇,占 3.5%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 4420232024: 2220242025: 332025

杭州有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断与预后淋巴瘤及肿瘤相关噬血治疗方案
论文中的科室风湿免疫科病理/检验科
牵头的论文14
  1. The clinical features and outcomes of aggressive large B cell lymphoma with concomitant hemophagocytic lymphohistiocytosis at diagnosis.2025Annals of hematology免费全文
  2. Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.2025Blood
  3. Tuberculosis-triggered cytokine storm with hemophagocytic lymphohistiocytosis and tuberculous spondylitis in an apparently immunocompetent host: a case report and literature review.2025Frontiers in immunology免费全文
  4. Clinical Features of Hepatic Manifestations among Adult Patients with Hemophagocytic Lymphohistiocytosis: A Retrospective Study.2024Acta haematologica
  5. Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.2024Cell transplantation免费全文
  6. Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial.2023American journal of hematology
  7. Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis.2023Annals of hematology
  8. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.2023Cytotherapy
  9. Case Report: Parvovirus B19 infection complicated by hemophagocytic lymphohistiocytosis in a heart-lung transplant patient.2023Frontiers in immunology免费全文
  10. Hemophagocytic Lymphohistiocytosis Secondary to Disseminated Histoplasmosis in HIV Seronegative Patients: A Case Report and Review of the Literature.2022Frontiers in cellular and infection microbiology免费全文
  11. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.2022Frontiers in immunology免费全文
  12. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences免费全文
  13. Case Report: Hemophagocytic Lymphocytosis in a Patient With Glutaric Aciduria Type IIC.2021Frontiers in immunology免费全文
  14. Clinical Value of 18F-FDG PET/CT Scan and Cytokine Profiles in Secondary Hemophagocytic Lymphohistiocytosis in Idiopathic Inflammatory Myopathy Patients: A Pilot Study.2021Frontiers in immunology免费全文
中文论文(未计入)1
  1. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review.2023Journal of Zhejiang University. Science. B免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])正在招募NCT07208058研究中心III期2025-11 启动
PubMed 以外找到的论文(未计入)11
  1. Adult hemophagocytic lymphohistiocytosis: A multicenter retrospective analysis of etiology and impact on survival in China2025Blood会议摘要
  2. Early mortality and prognostic factors in diffuse large B-cell lymphoma presenting with hemophagocytic lymphohistiocytosis2025Blood会议摘要
  3. Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia2025Blood会议摘要
  4. Single-cell transcriptomics reveals monocytic glycolytic reprogramming in lymphoma-associated hemophagocytic lymphohistiocytosis2025Blood会议摘要
  5. A Respective Analysis of EBV DNA Status in T/NK Cell Lymphoma Associated-Hemophagocytic Lymphohistiocytosis2023Blood会议摘要
  6. Massive Digestive Tract Bleeding Caused by EBV-Triggered Hemophagocytic Lymphohistiocytosis and Digestive Tract Vascular Malformation2022Cancer Research and Cellular Therapeutics论文
  7. P1243: RUXOLITINIB COMBINED WITH DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INTERIM ANALYSIS OF A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE 2 CLINICAL TRIAL2022HemaSphere会议摘要
  8. Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up2022Blood论文
  9. Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial2022Blood论文
  10. Warburg effect secondary to diffuse large B‑cell lymphoma-associated hemophagocytic lymphohistiocytosis: a case report2022Research Square预印本
  11. Ruxolitinib Combined with Dexamethasone in Adult Patients with Secondary HLH:a Single-Centre Pilot Trial2021Blood会议摘要

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

杭州有 7 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 1 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

杭州有 5 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

杭州有 3 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题视神经与视力影像抗体与诊断
论文中的科室神经内科眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

杭州有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题诊断与鉴别肾脏、腹膜后与血管
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年没有牵头重症肌无力的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

杭州有 6 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
    分期
    早期I期
    开始
    2025-04
    登记号
    NCT06933563

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、遵义、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis即将招募NCT06933563牵头方(推断)早期I期2025-04 启动
  2. An Exploratory Clinical Study of GC012F Injection for Refractory gMG已撤回NCT06419166牵头方(推断)早期I期2024-12 启动
  3. Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis状态不明NCT05828225牵头方(推断)I期2023-04 启动
  4. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.正在招募NCT06447597研究中心II/III期2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.0%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

杭州有 3 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
    分期
    早期I期
    开始
    2024-09
    登记号
    NCT06650319

    年龄 10 岁 至 60 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

  2. 即将招募
    Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
    分期
    I/II期
    开始
    2026-06
    登记号
    NCT07641140

    年龄 18 岁 至 60 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传学(ATP7B)诊断与铜代谢检测治疗(螯合剂、锌剂)

打开 PubMed 检索ClinicalTrials.gov

其他疾病

胆道闭锁

Biliary atresia

2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

杭州有 2 家医院列在胆道闭锁下全国有 31 家医院列在胆道闭锁下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。

这些数字背后的记录
研究主题筛查与诊断肝移植

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 222025

杭州有 6 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年没有牵头肝包虫病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 1 家医院列在肝包虫病下全国有 44 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

杭州有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.6%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 0020242025: 112025

杭州有 10 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
牵头的论文2
  1. Arrhythmias and clinical outcomes in Fabry disease with cardiac and renal involvement.2025Orphanet journal of rare diseases
  2. Generation of an induced pluripotent stem cell line (ZJUi007-A) from a 11-year-old patient of Fabry disease.2021Stem cell research
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease即将招募NCT06819514研究中心I/II期2025-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 7 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科风湿免疫科
牵头的论文2
  1. Predictors of anti-TNF treatment failure in intestinal Behçet's disease: a multicenter retrospective cohort study.2025Clinical rheumatology
  2. Ischaemic heart disease in Behçet's syndrome: a systematic review and meta-analysis.2022Clinical and experimental rheumatology
中文论文(未计入)1
  1. [Pathogenesis and treatment progression of myelodysplastic syndrome combined with Behçet's syndrome].2025Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
早期论文(2016–2020 年)1
  1. Is Helicobacter pylori associated with Behçet's syndrome? A meta-analysis.2019Helicobacter
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 4 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

杭州有 10 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
牵头的论文2
  1. Urinary Sodium Excretion and Kidney Disease Progression in IgA Nephropathy: A Cohort Study.2025American journal of nephrology
  2. Effect of finerenone on proteinuria reduction in IgA nephropathy.2025Renal failure
早期论文(2016–2020 年)4
  1. Updated Oxford classification and the international study of kidney disease in children classification: application in predicting outcome of Henoch-Schönlein purpura nephritis.2019Diagnostic pathology
  2. Changes in the diagnosis of glomerular diseases in east China: a 15-year renal biopsy study.2018Renal failure
  3. Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy: a systematic review and meta-analysis.2017Oncotarget
  4. Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity.2016Oncotarget
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases进行中,不再招募NCT06786338研究中心II期2025-06 启动
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  4. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  5. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 2 家医院列在戈谢病下全国有 40 家医院列在戈谢病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
    分期
    不分期
    开始
    2023-11
    登记号
    NCT06162338

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I正在招募NCT06162338牵头方(推断)不分期2023-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年中国大陆作者发表的 16 篇尼曼-匹克病 C 型 PubMed 英文论文中,这家医院牵头了 1 篇,占 6.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 3 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 2 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.3%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

杭州有 7 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文4
  1. The fecal microbiota of patients with primary biliary cholangitis (PBC) causes PBC-like liver lesions in mice and exacerbates liver damage in a mouse model of PBC.2024Gut microbes
  2. Single-cell RNA sequencing reveals the pro-inflammatory roles of liver-resident Th1-like cells in primary biliary cholangitis.2024Nature communications
  3. IL-17A produced by invariant natural killer T cells and CD3+ CD56+ αGalcer-CD1d tetramer- T cells promote liver fibrosis in patients with primary biliary cholangitis.2022Journal of leukocyte biology
  4. The Salivary Microbiota of Patients With Primary Biliary Cholangitis Is Distinctive and Pathogenic.2021Frontiers in immunology
早期论文(2016–2020 年)6
  1. TCRβ repertoire of memory T cell reveals potential role for Escherichia coli in the pathogenesis of primary biliary cholangitis.2019Liver international : official journal of the International Association for the Study of the Liver
  2. Reactive lymphoid hyperplasia of the liver: A case report.2019Medicine
  3. No difference in TCRβ repertoire of CD4+ naive T cell between patients with primary biliary cholangitis and healthy control subjects.2019Molecular immunology
  4. Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis.2017Scientific reports
  5. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis.2016Environmental microbiology
  6. Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.2016The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  2. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动
  3. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis进行中,不再招募NCT05050136研究中心II期2021-09 启动
  4. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 4.0%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

杭州有 6 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 3 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
牵头的论文1
  1. Whole-genome sequencing identified ALK as a novel susceptible gene of Hirschsprung disease.2025Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 4 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

浙江大学医学院附属第一医院

First Affiliated Hospital, Zhejiang University

杭州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
First Affiliated Hospital of Zhejiang University; Branch of First Affiliated Hospital of Zhejiang University; Beilun Branch of the First Affiliated Hospital; Sanmen Branch of the First Affiliated Hospital; First Affiliated Hospital Zhejiang University; Zheda Hospital; Zhejiang Provincial First Hospital

提出更正下载数据